

# **Vacc-iNTS Kick-off Meeting**

### 24<sup>th</sup>-25<sup>th</sup> October 2019

Accademia dei Fisiocritici Piazzetta Silvio Gigli 2, Siena (Italy)

## Agenda

#### Day 1: 24<sup>th</sup> October 2019

	OPENING SESSION
	Chair: Donata Medaglini (UNISI, SVA)
14:00	Welcome address
14:00	The Vacc-iNTS project: strategy and objectives – Donata Medaglini (UNISI, SVA)
Session I:	PLANNING AND EVALUATION OF INTS VACCINE DEPLOYMENT IN AFRICA
	Chairs: John Crump (UNI OF OTAGO) and Florian Marks (UCAM)
14:25	iNTS and Neglected Tropical Disease/Febrile illness classification (WP8) – Gianluca Breghi (SVA/FAS)
14:45	Epidemiology of iNTS disease (WP8) – John Crump (UNI OF OTAGO)
15:05	Mathematical modelling of iNTS disease burden in Sub-Saharan Africa (WP8) – Florian Marks (UCAM)
15:25	Cost-of-Illness and Cost-Effectiveness analyses for the introduction of an iNTS vaccine in Sub-Saharan Africa (WP9) – Florian Marks (UCAM)
15:45	
	relevant for a multi-year advocacy plan for iNTS (WP 9) – Stefano Malvolti (MMGH)
16:05-16:15	
	General discussion
16:15-16:45	General discussion Coffee break
16:15-16:45 Session II:	General discussion <i>Coffee break</i> CLINICAL TRIAL Chairs: Allan Saul (GVGH) and Audino Podda (GVGH)
16:15-16:45 Session II: 16:45	General discussion <i>Coffee break</i> CLINICAL TRIAL Chairs: Allan Saul (GVGH) and Audino Podda (GVGH) iNTS-GMMA vaccine background (WP1) – Rocio Canals Alvarez (GVGH)
16:15-16:45 Session II: 16:45	General discussion <i>Coffee break</i> CLINICAL TRIAL Chairs: Allan Saul (GVGH) and Audino Podda (GVGH)
16:15-16:45 Session II: 16:45 17:05	General discussion <i>Coffee break</i> CLINICAL TRIAL Chairs: Allan Saul (GVGH) and Audino Podda (GVGH) iNTS-GMMA vaccine background (WP1) – Rocio Canals Alvarez (GVGH) Vaccine manufacturing and stability assessment of vaccine lots (WP1-2) – Laura
16:15-16:45 Session II: 16:45 17:05	General discussion <i>Coffee break</i> CLINICAL TRIAL Chairs: Allan Saul (GVGH) and Audino Podda (GVGH) iNTS-GMMA vaccine background (WP1) – Rocio Canals Alvarez (GVGH) Vaccine manufacturing and stability assessment of vaccine lots (WP1-2) – Laura Martin (GVGH)
16:15-16:45 Session II: 16:45 17:05 17:25 17:45	General discussion <i>Coffee break</i> CLINICAL TRIAL Chairs: Allan Saul (GVGH) and Audino Podda (GVGH) iNTS-GMMA vaccine background (WP1) – Rocio Canals Alvarez (GVGH) Vaccine manufacturing and stability assessment of vaccine lots (WP1-2) – Laura Martin (GVGH) CTA and Phase I (stage I) clinical study in Europe (WP3) – Maheshi Ramasamy (UOXF)
16:15-16:45 Session II: 16:45 17:05 17:25 17:45 18:05-18:15	General discussion <i>Coffee break</i> CLINICAL TRIAL Chairs: Allan Saul (GVGH) and Audino Podda (GVGH) iNTS-GMMA vaccine background (WP1) – Rocio Canals Alvarez (GVGH) Vaccine manufacturing and stability assessment of vaccine lots (WP1-2) – Laura Martin (GVGH) CTA and Phase I (stage I) clinical study in Europe (WP3) – Maheshi Ramasamy (UOXF) Phase I (stage II) clinical study in Africa (WP4) – Anthony Scott (UOXF/KWTRP)

### Day 2: 25<sup>th</sup> October 2019

Session III:	IMMUNE RESPONSE ANALYSIS
	Chair: Maheshi Ramasamy (UOXF)
09:00	Serological analysis of Vacc-iNTS clinical trial samples (WP5) – Laura Martin (GVGH)
09:20	Exploratory immunological analyses (WP6) - Maheshi Ramasamy (UOXF)
09:40	Computational analysis of multiparametric flow cytometry data (WP6) – Annalisa Ciabattini (UNISI)
10:00-10:20	General discussion
10:20-10:50	Coffee break
Session IV:	SERO-EPIDEMIOLOGY STUDIES
	Chair: Melita Gordon (UOL)
10:50	Sero-epidemiology studies: Malawi field site (WP7) – Melita Gordon (UOL)
11:05	Sero-epidemiology studies: Burkina Faso field site (WP7) – Soura Bassiahi (UO)
11:20	Sero-epidemiology studies: Ghana field site (WP7) – Ellis Owusu-Dabo (KNUST)
11:35	Sero-epidemiology studies: Kenya field site (WP7) – Sam Kariuki (KEMRI)
11:50-12:10	General discussion
Session V:	TRAINING, MANAGEMENT, DISSEMINATION AND IMPACT ASSESSMENT
50331011 V.	Chair: Donata Medaglini (UNISI, SVA)
12:10	European training for students from disease endemic countries (WP10) – Donata Medaglini (UNISI, SVA)
12:20	Staff training in endemic countries (WP10) – Melita Gordon (UOL)
12:30	Management, Dissemination and Impact Assessment (WP11-18) – Diletta Magini (SVA)
12:40-12:50	General discussion
12:50-13:00	Concluding remarks and next steps - Donata Medaglini (UNISI, SVA) and Rino Rappuoli (SVA, GSK)
13:00-13:45	Lunch
14:00-15:30	Steering Committee meeting (SC members only)

This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No 815439

